SUMMARY
Diseases of the circulatory system are the main cause of disability and premature death in Ukraine. A great number of RCTs and meta-analyses proved high preventive efficiency of statins to reduce the cardiovascular risk. The aim of the study is to analyze the dynamics of cost and availability of statin drugs in Ukraine in 2012-2015. Dynamics of the prices for some statin drugs was determined according to the data of the “Pharmstandard” system of “Morion” company. To assess availability of the statin therapy the coefficient of the solvency adequacy was used. According to the results of the study it has been found that at the pharmaceutical market of Ukraine there is an adequate range of statin drugs. During the period from 2012 to 2015 there was the positive dynamics of the market structure – increase in domestic drug production and its share in the market structure. From 2014 there was the increase in prices for the vast majority of drugs of the statin group of both domestic and foreign production – the average for the group was 42.1% and 101.4%, respectively. The dynamics of the solvency adequacy indicates decrease in availability of statin drugs for the Ukrainian consumers in the period from 2012 to 2015. Under these conditions the possibility of the primary and secondary prevention of CVD is provided by high economic availability of domestic generic drugs, which range over the past four years has increased by 38%. Measures in the healthcare system, contributing to increase availability and the amounts of statin use in Ukraine are needed.